FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Virginia Klimek

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Treatment Outcome

Procedures

Physiology

Mutation

Anatomy

CD8-Positive T-Lymphocytes

Co-author Network

Publications

TOP 3
Thomas Fischer; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Elihu Estey; Carlo Lanza; Edward Fox; Gerhard Ehninger; Eric J Feldman; Gary J Schiller; Virginia Klimek; Stephen D Nimer; D Gary Gilliland; Catherine Dutreix; Alice Huntsman-Labed; Jodi Virkus; Francis J Giles
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Hani Hassoun; Carlos D Flombaum; V D D'Agati; B T Rafferty; A Cohen; Virginia Klimek; A Boruchov; T Kewalramani; L Reich; Stephen D Nimer; R L Comenzo
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Virginia Klimek; Sophia Fircanis; Peter Maslak; Ilhem Guernah; Michael Baum; Nian Wu; Katherine S Panageas; John J Wright; Pier Paolo Pandolfi; Stephen D Nimer
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Virginia Klimek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Thomas Fischer; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Elihu Estey; Carlo Lanza; Edward Fox; Gerhard Ehninger; Eric J Feldman; Gary J Schiller; Virginia Klimek; Stephen D Nimer; D Gary Gilliland; Catherine Dutreix; Alice Huntsman-Labed; Jodi Virkus; Francis J Giles
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):4339-45.
2008: Hani Hassoun; Carlos D Flombaum; V D D'Agati; B T Rafferty; A Cohen; Virginia Klimek; A Boruchov; T Kewalramani; L Reich; Stephen D Nimer; R L Comenzo
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Bone marrow transplantation 2008;42(6):405-12.
2008: Virginia Klimek; Sophia Fircanis; Peter Maslak; Ilhem Guernah; Michael Baum; Nian Wu; Katherine S Panageas; John J Wright; Pier Paolo Pandolfi; Stephen D Nimer
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):826-32.
2008: Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles Alan Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Blood 2008;111(1):86-93.
2006: David H Chang; Nancy Liu; Virginia Klimek; Hani Hassoun; Amitabha Mazumder; Stephen D Nimer; Sundar Jagannath; Madhav V Dhodapkar
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Blood 2006;108(2):618-21.
2006: Andrew Lamb; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain I Saba
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Cancer 2006;106(8):1794-803.
2006: Raymond Comenzo; Hani Hassoun; Tarun Kewalramani; Virginia Klimek; Madhav V Dhodapkar; Lilian Reich; Julie T Feldstein; Martin Fleisher; Daniel A Filippa; Stephen D Nimer
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Leukemia 2006;20(2):345-9.
2006: Hani Hassoun; Lilian Reich; Virginia Klimek; Madhav V Dhodapkar; Adam Cohen; Tarun Kewalramani; Rachel Zimman; Lisa Drake; Elyn Riedel; Cyrus V Hedvat; Julie T Feldstein; Daniel A Filippa; Martin Fleisher; Stephen D Nimer; Raymond Comenzo
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
British journal of haematology 2006;132(2):155-61.
2005: Pierre W Wijermans; Michael Lübbert; Gregor Verhoef; Virginia Klimek; A Bosly
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Annals of hematology 2005;84 Suppl 1():9-17.
2005: S Gupta; Ping Zhou; Hani Hassoun; Tarun Kewalramani; Lilian Reich; S Costello; L Drake; Virginia Klimek; Madhav V Dhodapkar; Julie T Feldstein; Cyrus V Hedvat; Nagesh Kalakonda; Martin Fleisher; Daniel A Filippa; Jing Qin; Stephen D Nimer; Raymond Comenzo
Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
Bone marrow transplantation 2005;35(5):441-7.
2005: Richard M Stone; Daniel J DeAngelo; Virginia Klimek; Ilene Galinsky; Elihu Estey; Stephen D Nimer; Wilson Grandin; David Lebwohl; Yanfeng Wang; Pamela Cohen; Edward A Fox; Donna Neuberg; Jennifer Clark; D Gary Gilliland; James D Griffin
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Blood 2005;105(1):54-60.
2005: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; Elihu Estey; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary Schiller; Virginia Klimek; Stephen D Nimer; Alois Gratwohl; Chunaram Choudhary; Constan Mueller-Tidow; Hubert Serve; Harald Gschaidmeier; Pamela S Cohen; Christoph Huber; Thomas Fischer
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Richard M Stone; J De Angelo; Ilene Galinsky; Elihu Estey; Virginia Klimek; W Grandin; D Lebwohl; A Yap; P Cohen; Edward A Fox; Donna Neuberg; J Clark; D Gary Gilliland; James D Griffin
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Annals of hematology 2004;83 Suppl 1():S89-90.
2003: Shin-ichiro Fujii; Kanako Shimizu; Virginia Klimek; Matthew D Geller; Stephen D Nimer; Madhav V Dhodapkar
Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.
British journal of haematology 2003;122(4):617-22.
2002: Virginia Klimek; Linda Williams; Paul B Chapman
Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Cytokines, cellular & molecular therapy 2002;7(2):71-4.
2002: Susanne G Schaed; Virginia Klimek; Katherine S Panageas; Cristina Musselli; Leah Butterworth; Wen-Jen Hwu; Philip O Livingston; Linda Williams; Jonathan J Lewis; Alan N Houghton; Paul B Chapman
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):967-72.
2000: Virginia Klimek; Jedd D Wolchok; Paul B Chapman; Alan N Houghton; Wen-Jen Hwu
Systemic chemotherapy.
Clinics in plastic surgery 2000;27(3):451-61, ix-x.
1999: Jedd D Wolchok; Virginia Klimek; Linda Williams; Paul B Chapman
Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy.
Cytokines, cellular & molecular therapy 1999;5(4):205-6.